tiprankstipranks
Mirati Therapeutics (MRTX)
NASDAQ:MRTX

Mirati Therapeutics Stock Forecast & Price Target

298 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Strong Buy
10Ratings
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Mirati
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRTX Stock Price Prediction

Average Price Target

$108.30
▲(60.30% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $108.30 with a high forecast of $154.00 and a low forecast of $80.00. The average price target represents a 60.30% change from the last price of $67.56.
Highest Price Target$154.00Average Price Target$108.30Lowest Price Target$80.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Cowen & Co.
Buy
Reiterated
Cowen reiterates Outperform Rating on Mirati Therapeutics (MRTX)Cowen analyst Tyler Van Buren reiterated an Outperform rating and {REMOVEPT} price target on Mirati Therapeutics (NASDAQ: MRTX)
Evercore ISI
Buy
Reiterated
Mirati Therapeutics (MRTX) Received its Third Buy in a Row
Guggenheim
$115.00
Buy
70.22%
Upside
Upgraded
Mirati Therapeutics upgraded to Buy from Neutral at GuggenheimMirati Therapeutics upgraded to Buy from Neutral at Guggenheim
Oppenheimer
$105.00
Hold
55.42%
Upside
Reiterated
UPDATE: Mirati Therapeutics (MRTX) PT Lowered to $105 at OppenheimerOppenheimer analyst Jay Olson lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $105.00 (from $125.00) while maintaining a Perform rating.
Morgan Stanley
$100.00
Hold
48.02%
Upside
Reiterated
Mirati Therapeutics (MRTX) PT Lowered to $100 at Morgan Stanley Ahead of ASCOThe analyst reiterated an Equalweight rating, stating "top-line results indicated a 43% ORR, which compares favorably to Amgens Lumakras and we expect focus on durability data (PFS and OS) at the meeting.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MRTX Stock Forecast FAQ

What is MRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirati Therapeutics’s 12-month average price target is $108.30.
    What is MRTX’s upside potential, based on the analysts’ average price target?
    Mirati Therapeutics has 60.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRTX a Buy, Sell or Hold?
          Mirati Therapeutics has a conensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mirati Therapeutics’s price target?
            The average price target for Mirati Therapeutics is $108.30. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $154.00 ,the lowest forecast is $80.00. The average price target represents 60.30% Increase from the current price of $67.56.
              What do analysts say about Mirati Therapeutics?
              Mirati Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis